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ABSTRACT 
 
Objectives: The increased use of hematopoietic stem cell transplant (HSCT) for 
its potentially curative properties has led to studies examining the quality of care 
that is currently received. More specifically, research examining the timeliness 
aspect of quality of care is being addressed. This study was therefore designed 
to examine timeliness of obtaining HSCT on two levels, the approval time period, 
and the time it takes to receive the transplant, based off of payer type.    
Methods: University of Nebraska Medical Center (UNMC) patients 
recommended for a HSCT were analyzed according to payer type (private vs. 
Medicare/Medicare) between the years of 2007 and 2011. Within this time 
period, 1389 patients were recommended for a HSCT. This sample size was 
divided into two cohorts of patients: not-transplanted and transplanted. Of these 
patients, 559 received the transplant. For statistical analysis purposes of this 
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study, we used data from the patients that had the procedure and had it funded 
by either a public payer (Medicare/Medicaid) or private payer. It was found that 
421 of these patients that were transplanted were covered by private insurance 
while 97 were on Medicare/Medicaid. We compared the patient-, disease-, and 
transplant-related characteristics according to payer. Univariate analyses were 
completed using Wilcoxon and Chi-square tests, while multivariate analyses 
were performed using multiple linear regression analysis.    
Results: Delays are currently seen during the approval process and the waiting 
period for receiving a HSCT, depending on the type of payer. It was found that 
patients who used public payers have a shorter time getting approved for the 
transplant; however, this group also took more time to receive transplant from the 
time of approval when compared to patients who used private payers. Other 
factors found to have a statistically significant association with timeliness of 
transplant included place of residence (urban vs. rural) and year of transplant.   
Conclusion: This study highlights areas in the process of receiving a HSCT that 
currently need changes. Differences in both the time to approval process and the 
time to receive the transplant depending on the payer type were observed. These 
disparities in the timeliness of receiving a potentially life-saving procedure 
suggest disparity in quality of care received, according to health care payer. 
System changes from the payer and the hospital to improve or eliminate the 
delays is recommended. 
 
  
 
 
 
 
 vii 
TABLE OF CONTENTS 
 
Title           i 
Reader’s Approval Page        ii   
Dedication Page         iii 
Acknowledgements         iv 
Abstract          v 
Table of Contents         vii 
List of Tables         ix 
List of Figures         x 
List of Abbreviations        xi 
Introduction          1 
 Hematopoietic Stem Cell Transplantation    1 
 Timeliness of HSCT as Indicator for Quality of Care   5 
Objectives          8 
Methods          10 
 Data Source         10 
 Patients         11 
 Variables Evaluated        12 
 Study Endpoints Evaluated      12 
 Statistical Analysis        13 
Results          15 
  
 
 
 
 
 viii 
 Summary of Patients Evaluated       15 
 Characteristics of HSCT Patients According to Payer   18  
Indices of Timeliness of HSCT       21  
Multivariate Analysis       24 
Discussion           27  
 Not-transplanted Cohort       27 
 High Percentage of Uninsured Patients in the United States  29 
 Medicare/Medicaid Delay       31 
 Private Payer Approval       33 
 Fixing Healthcare Delays       35 
 Strengths and Limitations to Current Study    35 
 Future Research and Recommendations    37 
References           39 
Vita           43 
  
 
 
 
 
 ix 
LIST OF TABLES 
 
 
Table Title Page  
1 Patient Characteristics According to Payers 19 
2 Multivariate Analysis 26 
   
   
   
   
   
   
   
   
   
   
 
  
 
 
 
 
 x 
LIST OF FIGURES 
 
 
Figure  Title Page  
1 Schema for Subject Selection in Payer Process for HSCT 17 
2 Time from Initiation of Payer Approval to Actual Approval 
by Payer Type 
22 
3 Time from Approval to Transplant by Payer Type 23 
   
   
   
   
   
   
   
   
   
 
  
 
 
 
 
 xi 
ABBREVIATIONS  
 
Allo-HSCT Allogeneic Hematopoietic Stem Cell Transplantation 
BCBS  BlueCross BlueShield 
CIBMTR  Center for International Blood and Marrow Transplant Registry  
CR1  First Complete Remission 
CR2+  Second Complete Remission 
GVHD  Graft-versus-Host Disease 
HD  Hodgkin’s Disease 
HLA  Human Leukocyte Antigen 
HSCT  Hematopoietic Stem Cell Transplantation 
IOM  Institute of Medicine 
IRB  Institutional Review Board 
MDS  Myelodysplastic Syndromes 
MM   Multiple Myeloma 
NHL  Non-Hodgkin’s Lymphoma 
NMDP National Marrow Donor Program 
PIF  Primary Induction Failure 
REL  Relapse 
RUCA  Rural Urban Commuting Area Codes 
SES  Socio-economic Status 
TBI  Total Body Irradiation 
UNMC University of Nebraska Medical Center 
  
 
 
 
 
 1 
INTRODUCTION 
 
Hematopoietic Stem Cell Transplantation 
Hematopoietic stem cell transplantation (HSCT) offers the best curative 
method for certain types of cancers involving blood and bone marrow (Gratwohl 
et al., 2010). It was first introduced over fifty years ago and is now widely used 
today, allowing patients the greatest chance of cancer-free, long-term survival 
(Copelan, 2006). However, HSCT is a high risk and life-threatening procedure. It 
involves transplanting stem cells into the body to specialize into the necessary 
cells of the hematopoietic system. The hematopoietic stem cells used in this type 
of transplant are cells that are isolated from blood, bone marrow or umbilical cord 
blood and have the capability of maturing and/or differentiating into different cells 
of the hematopoietic system (Copelan, 2006). This process is usually completed 
after an individual has completed high dose chemotherapy, with or without 
radiation, to destroy all circulating malignant, as well as healthy hematopoietic 
cells. It is expected that the newly introduced stem cells will replenish the 
individual’s hematopoietic system thus rendering them cancer-free (NCI, 2010).   
One of the major benefits of receiving this type of transplant is that it 
allows the patient to undergo more intense chemotherapy or radiation 
treatments. An individual’s bone marrow has a limit before it is permanently 
damaged by the cancer treatments. By having this transplant as a treatment 
option, physicians are less limited in the intensity of the chemotherapy and 
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radiation treatments which allows for greater success in destroying the cancer 
causing cells (NCI, 2010; Perumbeti, 2012).   
Because HSCT is a high-risk procedure in all stages of the transplant (pre- 
peri-, short-term post-, and long-term post), in order to achieve successful 
results, many crucial steps are performed prior to the actual transplant. The type 
of HSCT that the patient will receive needs to be firstly established. There are 
generally two types of HSCT used in today’s hospitals: autologous and 
allogeneic transplantation (Copelan, 2006). An autologous transplant uses one’s 
own stem cells. Cells are extracted from the patient prior to the high intensity 
chemotherapy and/or radiation and then transplanted. This may not always be 
the best option due to the possibility of re-introducing cancer causing stem cells 
back into the body; however, it poses less threat of graft rejection since the cells 
introduced are not foreign stem cells (ACS, 2012). 
An allogeneic stem cell transplant involves transplanting matching donor 
cells with the recipient cell.  Donors can be related or unrelated to the recipient. 
Because the potential for rejection and post-transplant complications is higher for 
this type of transplant, patients must be healthy enough to undergo this type of 
treatment (NIH, 2011). Thus, highly medically co-morbid and elderly patients are 
generally not recommended for this type of HSCT.  The next crucial process 
once allo-HSCT is considered is finding the right donor. Usually siblings are first 
matched against the patient’s human leukocyte antigen (HLA) and followed by 
non-relatives when a sibling match is not found (Dzierzak-Mietla et al., 2012). 
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Finding a donor can be a timely process if a sibling donor is not available. 
According to the aplastic anemia and myelodysplastic syndromes (MDS) 
foundation (AAMDS, 2012), only about 3 in 10 people find a matched related 
donor. If no related donor is available, it can take a considerable amount of time 
to find a matched unrelated donor. To find a matched unrelated donor in the 
United States, the patient’s human leukocyte antigen (HLA) profile is compared 
against registries such as the National Marrow Donor Program (NMDP), to check 
for any suitable matches (NCI, 2010). This process can take an average of three 
months, but in some instances can take up to a year. In the end, some patients 
may receive the transplant from a donor that only partially matches their HLA 
profile, presenting a greater possibility of rejection (NMDP, 2013). 
During a HSCT, stem cells are administered usually in the form of an 
intravenous line lasting approximately an hour. This procedure usually causes no 
pain. The cells, after infusion, are expected to make their way to the bone 
marrow to begin reestablishing normal production of blood cells, also known as 
engraftment. Until normal levels of white blood cells, red blood cells and platelets 
are found within the body, the patient is generally required to stay in the hospital. 
Growth factors may be used to enhance this process if any delay is expected or 
seen (Copelan, 2006). This step can be an uneventful process or the persistence 
of non-engraftment could cause death. Patients are kept in the restricted hospital 
environment for usually two to four weeks to prevent contracting opportunistic 
infections since the immune system is compromised at this point. The 
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immunocompromised state of the patient renders them vulnerable to multiple 
complications (Spitzer, 2001).  
There are numerous side effects or complications from the treatments 
involved in HSCT. For example, there are numerous side effects initially that are 
associated with the administration of chemotherapy/radiation including nausea, 
vomiting, mucositis, loss of hair, infertility, organ toxicity and secondary cancers, 
to name a few (Spitzer, 2001). There are also numerous possible complications 
with the transplant itself. For example, graft-versus-host disease (GVHD) occurs 
in 10-50% of patients post allogeneic HSCT (NIH, 2011). This involves the donor 
cells attacking the cells and organs of the patient. Due to this being the greatest 
threat involved in allogeneic HSCT, medications are given to help prevent this 
from happening. GVHD is not a threat in autologous HSCT since donor cells are 
not used. Any of these above medical events can cause treatment failure and/or 
death with HSCT (Andre-Schmutz, 2002).  
Post-transplantation, patients are admitted on the average of three weeks 
depending on the complications. Patients are generally followed weekly up to 
100 days and gradually spreading out to every two weeks, then once a month for 
one year. During the post-transplantation period, patients can remain disease 
free, develop further complications, progress or relapse, or die (NIH, 2011).  
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Timeliness of HSCT as Indicator for Quality of Care 
As described above, HSCT can be a prolonged process and usually starts 
from carefully examining the type of patients who may benefit from it. It is also a 
very expensive procedure that can cost up to $102,574 (Saito et al., 2008). 
Because of the prohibitive cost of the procedure, not only is patient selection 
tedious, but also the payer’s prior approval is required. The payer approval 
process involves a series of communication between the medical team and the 
payer and usually entails a significant amount of paperwork. Typically, a patient 
being considered for HSCT is referred to a transplant physician by a 
hematologist/oncologist. An initial physician visit and pre-transplant testing 
ensues and would determine if the HSCT is indeed recommended. This process 
involves analyzing previous medical records, obtaining an accurate medical 
history, and undergoing a comprehensive medical physical exam. The pre-
transplant testing also involves numerous tests to assess the status of the 
patient’s disease and to make certain that the patient would in fact benefit from a 
HSCT. The information obtained from the initial visit and the pre-transplant 
testing is generally enough to allow the insurance company to make an approval 
decision. If the patient is deemed a good candidate for a transplant, the 
necessary paperwork is sent to the insurance company with the recommendation 
that the patient should be approved for a transplant (NMFF, 2013). To date, it is 
not known how lengthy is the waiting period from initiation of payer approval to 
obtaining payer approval and to the actual performance of the HSCT. The 
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expectation is that this time frame is rather quick since the need for HSCT may 
be time-sensitive. This time frame is referred to as ‘timeliness’ of care. 
Timeliness is defined as the ability to obtain necessary care, and minimizing 
avoidable delays to obtaining the care (Envisioning the National Health Care 
Report, 2001). Timeliness is also a measure of the quality of care a patient 
receives. The issue of timeliness is a critical component to care, especially for 
patients being treated for cancer. Payers can potentially play a major role in 
determining the timeliness of care. The Institute of Medicine (IOM) Committee on 
the Quality of Health Care in America considers timeliness to be one of four 
categories for measuring quality of care, with the other three being safety, 
effectiveness, and patient centeredness (Envisioning the National Health Care 
Report, 2001). The IOM further describes timeliness as  
“composed of three points: 1) Access to the system of care, 
2) Timeliness in getting to care for a particular problem, and 
3) Timeliness within and across episodes of care” 
(Envisioning the National Health Care Report, 2001).  
 
Studies have shown various factors determine one’s ability to access the 
system of care. These factors included: age, sex, race/ethnicity, and socio-
economic status (SES) (Ward et al., 2008; Hwang et al., 2004; Li et al., 2003; 
Majhail et al., 2010; Mandelblatt et al., 1999; Bradley et al., 2011; Penson et al., 
2001; Halpern et al., 2008; Khera et al., 2011; Bryce et al., 2010; Gornick, 1999; 
& Carlisle et al., 1997). Other studies also indicate, even among individuals who 
have access to health care, the many issues involved in obtaining the 
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appropriate care needed depending on their medical payer type (Ayanian et al., 
1993; Ward et al., 2008; Kwok et al., 2010; Chen et al., 2007; Mandelblatt et al., 
1999; Khera et al., 2012; Bradley et al., 2012; Penson et al., 2001; Halpern et al., 
2008; Harlan et al., 2005; Schweitzer et al., 2003; Bryce et al., 2010; Laurentine 
et al., 2010; & Carlisle et al., 1997). This has also been shown to have affected 
clinical outcomes, including among cohort who underwent HSCT (Ayanian et al., 
1993; Ward et al., 2008; Kwok et al., 2010; & Li et al., 2003). This study was 
therefore designed to describe the timeliness of HSCT according to payer in a 
cohort of patients with hematologic malignancies being evaluated for possible 
HSCT. Additionally, we sought to determine if patient-, disease- and treatment 
factors affect timeliness of HSCT. By gaining more knowledge about timeliness in 
receiving HSCT, we are identifying areas where delays can be avoided and thus 
providing patients better quality of healthcare.  
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OBJECTIVES 
 
Today, it is established that every patient deserves the best quality of 
care, regardless of the patient’s individual characteristics. However, research has 
shown that many variables can affect the quality of care received by specifically 
affecting the timeliness. Studies have provided adequate evidence showing that 
payer type can impact the quality of care and clinical outcomes (Ayanian et al., 
1993; Ward et al., 2008; Kwok et al., 2010; Chen et al., 2007; Mandelblatt et al., 
1999; Khera et al., 2012; Bradley et al., 2012; Penson et al., 2001; Halpern et al., 
2008; Harlan et al., 2005; Schweitzer et al., 2003; Bryce et al., 2010; Laurentine 
et al., 2010; & Carlisle et al., 1997). However, in HSCT, the association between 
timeliness of receiving HSCT according to payer type is unknown. Examining this 
issue allows for better understanding of the role payers have in potentially 
causing a delay in an individual’s ability to receive HSCT. Additionally, this study 
will identify factors that may be associated with such delay.  
This study has the following three objectives: 
1) To compare the patient-, disease-, and transplant-related 
characteristics of HSCT patients with hematological malignancies 
according to the type of healthcare payers (private payer versus public 
payer - Medicare/Medicaid). 
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2) To compare time from initiation of payer approval to actual payer 
approval according to healthcare payer while adjusting for patient-, 
disease-, and transplant-related factors. 
3) To compare time from payer approval to performance of HSCT 
according to type of healthcare payer while adjusting for patient-, 
disease-, and transplant-related factors. 
The findings of the study should guide transplant programs and payers in 
designing a system that better guarantees efficient delivery of HSCT among 
patients with hematological malignancies. 
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METHODS 
 
Data Source 
Two databases were used in this study: 1) the stem cell transplant 
database, and 2) the transplant insurance database. Both databases are housed 
in a web-based secure password-protected, Oracle-based database, known as 
ONCOBASE. The stem cell transplant database started in the early 1980s when 
the University of Nebraska Medical Center (UNMC), located in Omaha, 
Nebraska, began performing HSCT. To date, this database contains detailed 
information on all patients who have undergone HSCT at UNMC. The database 
contains detailed patient-, disease-, and treatment-related variables, as well as 
systematic evaluations of clinical outcomes of patients after HSCT. These 
evaluations include post-transplant complications, disease reoccurrence, 
progression, and survival status of the patients which are ascertained on all 
patients at least once a year. The evaluation information is collected annually on 
the patient anniversary date by trained clinical research associates. This same 
data are also reported to the Center for International Blood and Marrow 
Transplant Registry (CIBMTR). All patients who are kept in this database signed 
informed consent releases allowing their information to be collected and added to 
the database. The transplant insurance database is a separate database that 
UNMC maintains on all patients referred for possible HSCT. Information on 
patient’s insurance or payer coverage and status are gathered and entered in the 
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database at the time a patient is referred to the hematology/oncology service for 
evaluation of possible transplant. The database is maintained by one nurse 
coordinator who tracks all significant events as the patient gets further 
evaluation. It also contains all pertinent communication between UNMC and the 
insurance/payer as it relates to all aspects of the payer approval process. Entry 
on every patient evaluated for possible transplant is maintained and updated 
systematically. Patient and clinical information on patients who did not undergo 
transplant are not collected but minimal information regarding insurance/payer 
information is kept, including reason for not proceeding to transplant.  This study 
has been reviewed and approved by the Institutional Review Board (IRB) at 
UNMC.   
 
Patients 
The study included two population sets. The first set included all patients 
who were seen at UNMC between the years 2007 and 2011 for evaluation of 
possible HSCT for any malignant and non-malignant disease.  This set of 
patients was used to evaluate the proportions of patients who undergo transplant 
from an unbiased pool of patients referred for possible HSCT. This population 
was also used to evaluate the reasons why patients did not proceed to HSCT. A 
second population set, a subset of patients from the above population who 
underwent HSCT, was used to compare the timeliness of HSCT according to 
insurance/payer type. Since we do not collect detailed information on the patients 
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who did not proceed to HSCT, only those in the second cohort are described in 
detail in this study.    
 
Variables Evaluated 
The primary variable evaluated in our study was the type of healthcare 
payer the patients used for the funding of their HSCT. We compared the patient-, 
disease-, and transplant-related characteristics according to payer: private 
insurance or public payer (Medicare/Medicaid). Evaluation according to individual 
type of private insurers was not performed. The following variables were 
compared according to healthcare payer: age, sex, race, median household 
income (based on residential ZIP code), location of residence (based on the 
Rural Urban Commuting Area Codes (RUCA)), HCT-Co-morbidity Index, 
transplant type, disease type, disease stage at transplant, year of transplant, and 
the use of total body irradiation (TBI) as part of the conditioning regimen.  
 
Study Endpoints Evaluated 
The outcome of interest in this study is timeliness of care. Timeliness of 
care was operationally defined in this study using two time points. First, is the 
time frame to payer approval defined as time from initiation of payer approval to 
receipt of actual approval in days. Initiation of payer approval was abstracted 
from the transplant insurance database as the time the UNMC coordinator 
submitted the necessary forms to the payer and an acknowledgement of receipt 
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was made by the payer. The second endpoint is time of payer approval to actual 
transplant, also measured in days.   
 
Statistical Analysis 
Proportion of patients who proceeded to transplant and those who did not 
were expressed in percentages. Proportion of patients who did not proceed to 
transplant were also determined according to reasons and expressed in 
percentages. Patient-, disease- and transplant-related characteristics were 
described in median and range for continuous variables and percentages for 
categorical variables. Univariate comparisons of the characteristics of the 
patients who proceeded to transplant according to type of payer (private versus 
public) were performed using Wilcoxon test for continuous data and Chi-square 
test for categorical data. Multivariate analysis was performed using linear 
regression model. Separate model building was performed for the two time points 
of the study endpoint; that is time to payer approval and time from approval to 
transplant. In the model building, the covariate for payer type (private versus 
public) was held in all model building. All covariates listed in Table 1 were 
entered one at a time. Only covariates with a p-value of 0.05 were retained in the 
final model. As shown in Table 2, three separate multivariate analyses were 
performed to test for consistency of the results: 1) first model utilized all patients 
who proceeded to transplant, 2) second model consisted only of patients with 
lymphoma who received autologous transplants, and 3) third model consisted of 
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only patients with multiple myeloma who received autologous transplant. No 
models on patients receiving allogeneic transplant was performed since they 
were too few in number.     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 15 
RESULTS 
 
Summary of Patients Evaluated 
 Figure 1 shows how the overall population was evaluated in the study. 
This population represents all the patients that were referred to the transplant 
program at UNMC from the years 2007 to 2011. Within the five year study period, 
a total of 1389 were evaluated for possible HSCT. Of these, 830 (60%) patients 
did not proceed to HSCT. Reasons for not proceeding to HSCT as noted from 
the remarks in the insurance database included the following: 1) HSCT plan was 
denied by payer and no alternative payer was available; 2) patient expired during 
the time period of being evaluated for HSCT ( n = 113, 4%); 3) the clinical 
indication and/or patient’s medical condition did not warrant HSCT ( n = 256, 
31%); 4) patient’s condition deteriorated making the patient ineligible to receive 
HSCT ( n = 48, 6%); 5) patient refused to proceed to HSCT ( n = 89, 11%); 6) 
patient sought referral to other institutions ( n = 119, 14%), and 7) other unknown 
reasons ( n = 198, 24%).  The remaining 559 patients (40%) proceeded to 
received HSCT. Of the 559 patients, 521 (93%) received their first transplant at 
UNMC, 6 (1%) received a planned tandem transplant, while 32 (6%) received 
their second or third HSCT. Among the 521 who received HSCT for the first time, 
421 (80%) were financed by private insurers, while 97 (19%) were financed by 
public payers (Medicare or Medicaid). Three patients (1%) paid out of pocket for 
their transplant. The patient cohort further studied in this study included the 519 
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patients who proceeded to receive their first HSCT and were financed by either 
private insurers or public payers. 
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Characteristics of HSCT Patients according to Payer  
Table 1 below shows the comparison of the patient-, disease-, and 
transplant-related characteristics of the 518 patients who underwent a HSCT 
according to payer type.  Patients whose HSCT were financed by private health 
insurance were more likely to be younger (median age of 53 years vs. 58) more 
likely to be Caucasians (95% vs. 90%), more likely to have a higher median 
income ($21,991 vs. $20,553), more likely to live in urban areas (63% vs. 46%), 
and more likely to have no medical comorbid illnesses (50% vs. 32%) compared 
to patients whose HSCT were financed by public payers. Patients in the two 
payer groups were comparable in terms of sex, type of disease, disease stage at 
the time of HSCT, type of HSCT, use of TBI as part of conditioning regimen, and 
year of transplant.  .  
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Variables Private Medicare/Medica
id 
p-value 
N  421 97  
Median age in yrs. (range) 53 (14-74) 58 (22-77) <0.0001 
   < 40 (%) 79(19) 12(12) <.0001 
   40 – 60 (%) 237(56) 18(19)  
    ≥ 60 (%) 105(25) 67(69)  
Sex (%)   0.7370 
   Female  164(39) 36(37)  
   Male  257(61) 61(63)  
Race/Ethnicity (%)   0.0346 
   Caucasians, non-Hispanic 401(95) 87(90)  
   Non-Caucasians 20(5) 10(10)  
Median income* (range) 21991 (9121-
40564) 
20553 (11422-
33947) 
<0.0001 
   ≤ 20000 (%) 100 (24) 39 (40) 0.0052 
   20000 – 30000 (%) 248 (59) 48 (50)  
   30000 – 40000 (%) 63 (15) 6 (1)  
   > 40000 (%) 6 (1) 2 (2)  
   Unknown (%) 4 (1) 2 (2)  
RUCA (%)   0.0027 
   Rural  156(37) 52(54)  
   Urban  265(63) 45(46)  
Comorbidity Index (%)   0.01 
   0 210 (50) 31 (32)  
   1 , 2 128 (30) 38 (39)  
   > 2 79 (19) 27 (28)  
   Missing 4 (1) 1 (1)  
Diagnosis (%)   .0559 
   Non-Hodgkin lymphoma 
(NHL) 
212(50) 41(42)  
   Hodgkin lymphoma (HD) 39(9) 5(5)  
   Multiple Myeloma (MM) 89(21) 33(36)  
   Leukemia/Myelodysplastic 
syndrome (MDS) 
74(18) 15(15)  
   Other 7(2) 3(3)  
Table 1: Patient Characteristics according to Payer. This table shows the variables 
that were examined in this study, according to the type of payer used to fund the HSCT 
(private or public).   
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    Table 1 Continued: Patient Characteristics according to Payer.  
 
Disease stage at transplant 
(%) 
  0.0758 
    1st Complete remission / 
Chronic phase 
118 (28) 17 (18)  
   ≥ 2nd Complete Remission 
/ Chronic phase 
85 (20) 22 (23)  
   Primary Induction Failure  58 (14) 11 (11)  
   Relapse / Accelerated  64 (15) 12 (12)  
   Multiple Myeloma 89 (21) 33 (34)  
   Other 7 (2) 2 (2)  
Year of Transplant (%)   0.6707 
   2007 65 (15) 13 (13)  
   2008 100 (24) 25 (26)  
   2009 84 (20 14 (14)  
   2010 101 (24) 25 (26)  
   2011 71 (17) 20 (21)  
Use of total body irradiation 
for conditioning (TBI) (%) 
  0.7427 
   TBI 30 (7) 6 (6)  
   No TBI 391 (93) 91 (94)  
Type of transplantation (%)   0.3028 
   Autologous 326 (77) 82 (85)  
   Unrelated 49 (12) 8 (8)  
   Related 46 (11) 7 (7)  
Median time from initiation of 
payer approval to approval, 
days (range) 
 
4 (0 – 90) 
 
0 (0 – 28) 
 
<0.0001 
Median time from approval to 
actual transplant, days 
(range) 
 
39 (-6 – 402) 
 
65 (14 – 277) 
 
<0.0001 
Median total time from 
initiation of payer approval to 
transplant, days (range) 
 
48 (1-407) 
 
66 (14-277) 
 
<0.001 
 
*Median income inferred from median household income based on residential ZIP             
codes. 
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Indices of Timeliness of HSCT 
Figures 2 and 3 shows the graphical representation of the time in days it 
took from initiation of payer approval to receipt of actual payer approval (Figure 
2) and the time in days it took from payer approval to performance of actual 
HSCT (Figure 3) according to individual insurance companies and public payers. 
As shown in Figure 2, patients who had private health insurance had a longer 
median time to wait from initiation of payer approval to the actual approval 
compared to patients who were Medicare or Medicaid eligible (median time in 
days 0 (range 0 to 28) vs. 4 (range 0 to 90); p <0.001). Figure 2 also shows the 
relatively wide variation in the time to payer approval among private insurers from 
1 to 6 days and with a wide range of 0 to 90 days. Alternatively, public payers 
take 0 to 2 days with a range of 0 to 28 days.  Figure 3 shows the graphical 
representation of the time period from payer approval to receipt of the actual 
HSCT.  As shown in this figure, there is a significantly longer wait time for 
patients funded  by public payers compared to private payers (median time in 
days 65 (range 14-277) vs. 39 (range -6 to 402); p <0.001). The negative value 
depicts patients who actually proceeded to HSCT without having received yet 
final approval from the insurance company. The graph also shows that while the 
median time from payer approval to actual HSCT is significantly longer for 
patients funded by public payers, the variation in range is much narrower among 
those funded by public payers than those among private payers (maximum wait 
time of 277 days vs. 402 days).  
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Multivariate Analysis 
Table 2 shows the results of the multivariate analysis evaluating the 
association between the types of payer (private versus public) with the two 
outcomes or indices of timeliness (time to payer approval and time from payer 
approval to HSCT). In the first model, where all patients who proceeded to HSCT 
were included, the analysis showed that public payers were significantly faster in  
approval process time by a coefficient of 5.69 days compared to private payers  
(p value of <0.0001). Only year of transplant was significantly associated with this 
index of timeliness, such that there was a significant modest decrease in the time 
to payer approval over the years (coefficient of -0.77 days). On the other hand, 
the time it took to proceed to transplant after payer approval was significantly 
longer among HSCT funded by public payers compared to private payers at a 
coefficient of 24.69 days, p <0.0001. Interestingly no other patient-, disease-, and 
transplant-related variables were associated with this outcome aside from place 
of residence. The table shows that patients who lived in rural areas took longer to 
proceed to HSCT after payer approval at a coefficient of 9.38 days, p = 0.0365. 
This suggests that the delay in actual receipt of HSCT may be related to the 
logistics of having to reside in an area farther from the transplant center.    
To better evaluate the association between the indices of timeliness and 
payer type we evaluated this relationship using two other more homogenous 
disease models. Model 2 consisted of patients that had non-Hodgkin lymphoma 
(NHL) who proceeded to autologous HSCT, and Model 3 consisted of patients 
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with multiple myeloma who are at least 60 years of age and also received 
autologous HSCT.  No models on allogeneic HSCT were tested because we did 
not have adequate sample to carry a robust multivariate analysis.   
As shown in Table 2, Models 2 and 3 also found similar results to those of 
Model 1, that is, public payer approval took significantly less time, but also took 
significantly longer time to proceed to HSCT after payer approval when 
compared to private payer. Again, place of residence was found to be associated 
with time to actual HSCT in the NHL model, such that patients living in rural 
areas took significantly longer time to undergo HSCT after payer approval at a 
coefficient of 14.19 days. No other factors were found to be associated with the 
indices of timeliness.   
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DISCUSSION 
 
This study showed some relatively novel findings related to the timeliness 
of care in the process of obtaining payer approval and receipt of HSCT. 
Specifically, we showed that the approval time for patients having a public payer 
(Medicare/Medicaid) had, on average, less of a waiting period compared to 
patients using private health insurance.  Alternatively, these same patients that 
used public payers had a longer delay in receiving the actual transplant, when 
compared to the patients having private health insurance. Since timeliness of 
care is one parameter of quality of care, one can argue that there appears to be 
a wide variation in the quality of care received by HSCT patients according to 
payer type. Given these findings, it is important to understand what this delay 
potentially means and develop ways to potentially improve the quality of care and 
perhaps experience of HSCT patients.  Based on our findings, there is room for 
improving the timeliness of obtaining HSCT across the type of payer.  
 
Not-transplanted Cohort  
 As seen in Figure 1, from the original sample size of 1389 patients, only 
559 patients (40%) were actually transplanted, leaving 830 (60%) not 
transplanted. As mentioned, this procedure possesses potentially curative 
qualities, allowing patients with malignant and non-malignant disorders a better 
than usual chance of long-term, cancer-free survival. The 60% of patients who 
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were not transplanted for varied reasons, including denied, expired, not 
recommended, became ineligible, patient decided not to, referred, or other. With 
the substantial potential benefits to receiving HSCT, it would seem more likely 
that the proportion of patients transplanted would be greater than 40%, however 
this is not the case. An important question here is if the timeliness of care had 
any effect on the rather high percentage of patients that ended up not receiving 
HSCT. We were not able to study the characteristics of the not-transplanted 
cohort, but it would be interesting to evaluate if the characteristics of these 
patients have any associations with the type of payer they had.  An interesting 
question to be made is if the delay in time from approval to receiving the 
transplant in both payer types was not observed or is non-existent, would more 
patients actually receive HSCT?  
 Another interesting point to make among this cohort of not-transplanted 
patients is that the number of patients denied for the HSCT procedure was quite 
low. Only 7 patients (1%) of this cohort were not able to receive a HSCT due to 
insurance denial. This is a rather surprising finding that bodes well about how the 
payers view HSCT as a potentially useful treatment modality for diseases of the 
hematopoietic system. If a patient has medical coverage or is eligible for public 
financing, payers do, in fact, work with hospitals to ensure that their patient gets 
the recommended treatment and not get unduly denied.   
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High Percentage of Uninsured Patients in the United States  
This study evaluated a representative sample of patients with malignant 
and non-malignant disorders recommended for HSCT to a university center in 
the state of Nebraska between the years of 2007 and 2011. We identified two 
cohorts: not-transplanted and transplanted and used data from patients who 
underwent HSCT to evaluate how the payer approval process affect the timing of 
HSCT given the many anecdotal stories about how unreasonable insurance 
companies are in denying access to care. This study question is rather 
unexplored and for the most part unknown in the setting of HSCT. The study 
showed that a higher percentage of patients who eventually went into HSCT had 
private insurance other than Medicare/Medicaid (421 (80%) vs. 97 (19%)). 
According to Census Bureau Data (2010), approximately 48 million Americans do 
not possess healthcare insurance. As mentioned, HSCT is an expensive 
procedure.  Thus, our findings suggest that individuals with health insurance 
preferentially have access to this treatment modality.  While Medicare covers 
individuals who are at least 65 years of age or have permanent disability (HHS, 
2013), this procedure is less used in the older population because of its 
associated toxicities. Medicaid, which is dedicated to elderly, disabled or low 
income people and families, specifies that to be considered low income, a 
family/person must have an income up to 133% of the poverty line, as well as 
meeting other requirements (HHS, 2013). Few people qualify for this. Thus, there 
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is a possibility that the low proportion of public financed HSCTs in our population 
reflects disparity in access to HSCT.   
 According to the Census Data Report (2010), 18% of employed workers in 
the United States are uninsured do not qualify for Medicare/Medicaid and do not 
have available health care coverage at work. Of the unemployed citizens, 46.2% 
are uninsured and do not qualify for Medicaid/Medicare. These are rather large 
percentages of uninsured people currently in the United States.  The reality of 
these statistics is that uninsured Americans are not able to obtain the appropriate 
care they may need due to its high costs. This is certainly something that can be 
said on in HSCT setting. Many studies have found that uninsured patients do not 
seek the proper health care that they need. A study done by Ayanian et al. 
(1993) found that uninsured patients with breast cancer had a higher percentage 
for mortality compared to insured patients. This study showed significant 
outcomes associated with breast cancer, early diagnosis and survival. Uninsured 
patients delay seeking medical care, thus presenting with a later staged cancer. 
A similar study carried out by Ward et al. (2008) also examined how insurance 
was associated with cancer care utilization and outcomes. They found that 
uninsured patients were half as likely as patients possessing private insurance to 
receive cancer screening tests. This showed that health insurance status affects 
screening, which affects the time to diagnosis and the time to receive a 
transplant, if necessary. Overall, this affects the quality of care by affecting 
timeliness.  
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 The above studies that showed differences in cancer stages, screening 
tests, and mortality between according to payer type may explain the low 
percentage of patients that were covered by Medicare/Medicaid in our study. Are 
patients that may potentially benefit from this treatment not seeking medical 
attention because they are uninsured and do not meet the requirements for 
obtaining Medicaid or Medicare? This may mean that the requirements of the 
Medicaid/Medicare system are too strict and perhaps changes need to be made 
within this system of healthcare to allow patients to obtain the proper medical 
care.  
 
Medicare/Medicaid Delay 
 As shown in Figures 2 and 3, patients having Medicare or Medicaid had 
quick approval of receiving a HSCT, compared to those having private insurance; 
however, there was a significant delay in receiving the transplant. This could be 
due to many reasons, including financial reasons. According to a study done in 
2003, 59% of hospitals actually lose money treating Medicare patients and 61% 
lose money treating Medicaid patients (AHA, 2003). This financial burden may 
explain why a significant delay in receiving HSCT for Medicare/Medicaid patients. 
Approximately only 48% of the cost of certain medical procedures is covered by 
Medicare, leaving the rest of the financial burden on the patient and the hospital. 
Hospitals are frequently losing money due to the patient’s inability to cover the 
remaining costs. Hospitals could therefore be presenting patients having public 
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coverage with longer delays to ensure that the patient would, in fact, medically 
benefit from the procedure, and that the financial loss they would be almost 
required to take by treating the patient will be worth it to both the hospital and 
patient. By examining them for a longer period of time, the hospital is given more 
time to ensure that the patient would remain healthy enough for this type of 
treatment. It would be interesting to examine the percentage of patients that had 
public assistance that were approved for the transplant, but did not obtain the 
procedure.  
 As shown in Table 1 of the patient characteristics according to payer type, 
the majority of the patients (54%) that were covered by public payers resided in 
rural areas. This was a significant finding we found to be associated with the 
delay among patients using public financing. Rural areas have poor access to 
care and often require distant travelling to acquire tertiary level type of care. With 
longer distances to hospitals, patients are not always able to seek the proper 
health care that is needed, thus possibly explaining the delays we found in our 
study.  
 The longer distance to receive care also imposes a financial burden on 
patients using public assistance. As shown in Table 1, patients having public 
assistance, on average, have less income compared to patients having private 
health insurance. Less income can present patients with challenges on getting to 
the hospital and maintaining the necessary health status to receive the 
transplant. Having less money for example does not allow patients the freedom 
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to always eat healthy, and lack of nutrition can potentially result in a delay in 
treatment due to diminished health status.  
Another important issue involving rural healthcare is that individuals 
residing in rural areas tend to be older than those from urban areas (AHA, 2013). 
Older patients generally have a greater number of health issues compared to 
younger populations. According to the CDC (2011), in the population of people 
65 years or older, 24.4% of this population were in poor health, compared to 10% 
of the entire population. Additionally, it was found that 30.4% had heart disease 
(compared to 11.8% of people 18 years and older), and 18.1% had cancer 
(compared to 6.3% of people 18 and over). These statistics show the decrease in 
health of elderly patients compared to the younger population. The delay found 
for Medicare/Medicaid patients in receiving HSCT may therefore be correlated to 
rural populations having older residents and decreased health status.  
 
Private Payer Approval  
  In Figure 2, examining the differences between approval times of the 
various private health insurance companies also leads us to ask various 
questions regarding how private insurance companies work in approving patients 
for this type of high-cost procedure. With private health insurance operating 
within the same system, it would seem more likely that their approval time would 
be similar, rather than being spread out between 1 to 5 days. What is also 
noteworthy, is that the range of approval times among the different private 
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insurers is vastly different, ranging from 0 to 90 days.  This leads us to wonder 
how companies, for example BlueCross BlueShield, have an approval time of 0 
days for some patients, and yet take as long as 90 days for other patients. The 
same can be asked of the other private insurers. Although this can also be said 
of public payers, the range in time to approval is not as wide as private insurers. 
These findings suggest that there are no universal criterion set to approve or 
deny patients for this treatment. Instead, the variation in practices among private 
insurers reflects differing systems that may be unduly delaying receipt of HSCT 
at least in some cases. One can only imagine how comorbid factors such as pre-
existing conditions, medications patient are currently taking, obesity, ethnic 
status, and level of income are possibly being used and may affect the decision 
process and thus causing greater delays than others.  
 Starting in January, 2014, this difference in approval within and across 
insurance companies may no longer be seen with the affordable care act that is 
expected to take effect. This care act has been structured to allow patients 
similar coverage across private insurance companies, if they chose to use a 
private over a public program.  This program will prevent insurance companies 
from denying patients the treatment due to co-existing conditions, and thus 
altered health statuses; however, whether or not it’s going to make it a more 
universal system across insurance groups, regarding issues such as this, 
remains unknown (Schwartz & Claxton, 2010). A primary goal of this program is 
to place limitations on the decision-making role of private companies. It is an 
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obvious area that needs addressed and further examined to understand why 
these differences in approval delay are seen.  
Fixing Healthcare Delays  
A second option for fixing the differences seen across approval and 
receiving transplant delays would be to develop a system of healthcare that is 
universal for each patient in the United States. The concept of single payer 
system may potentially further limit if not eliminate delays because insurance 
companies would no longer be allowed to compete for revenue. Approving 
patients based off of personal characteristics and approving patients for financial 
reasons would no longer be allowed since patients would receive treatments 
based off their medical need and not on their ability to pay for the treatment 
(PNHP, 2013). Each person would receive high-quality, comprehensive medical 
care and would not be forced to experience longer delays for treatments and 
would not be forced to pay higher co-pays for personal characteristics.  
 
Strengths and Limitations to Current Study 
This study, to our knowledge, is the first to have demonstrated the 
potential delay in obtaining HSCT according to payer. We used a representative 
sample of a rather unbiased patient pool with malignant and non-malignant 
hematologic disorders who have been referred for possible HSCT at UNMC. The 
data source used is the study included all patients referred within the five year 
study period. The population size is rather large and the cohorts were divided 
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according to how patients were managed in real time. The data also contained 
detailed dates and transaction details that allowed us to study closely the payer 
approval process in HSCT, something that has not been described before. We 
accounted for personal characteristics of each patient and found areas such as 
income, ethnicity, co-morbid index and patient disease to not have any significant 
correlation between the delays seen for being approved and receiving a HSCT. 
This study examined many variables and found differences in the timing of payer 
approval according to payer and place of residence.  
Given that our population represents only the experience of a single larger 
transplant center situated in Nebraska, our study may possess some limitations. 
We did not have an ethnically or racially diverse group of patients since 
Nebraska consists predominantly of Caucasian population. Our results indicate 
that only place of residence and year of transplant have any significant 
association to the timeliness of receiving HSCT. Perhaps, if our sample was 
more diverse, our results may have been different. Our cohort also consisted 
mostly of patients who underwent autologous transplant. The delays we found 
may not necessarily be true if more allogeneic transplants were included.  
Another limitation of our study is our inability to correlate how the delays we 
found in our study correlate with the experience of patients as they proceed into 
HSCT. 
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Future Research and Recommendations 
 An interesting area that could be further examined involves the second 
cohort of patients, the not-transplanted cohort. It would be worthwhile to examine 
the patient characteristics according to payer type as was done with the 
transplanted cohort. It would allow us to understand if any patient characteristics 
and/or payer type are associated with the reasons for not being transplanted. 
This is an area we plan on further analyzing.  
 Another area we anticipate further study is to assess the effect (if any) that 
the delays seen in our study have on the outcome of HSCT, such as survival. 
However, it is important to note that timeliness in itself is noteworthy as it deals 
with actual processes that affect quality of care. While our study showed 
significant variations in the approval process of payers in HSCT, we still do not 
understand how much of these variations can be improved. Without system wide 
changes in approval process across types of payers, improvements designed at 
the hospital level may not necessarily improve timeliness. Making private 
insurers aware of the delay we found in our study may promote policy reviews 
among insurance companies and help improve the approval process. On the 
other hand, hospitals can also make changes within their system to eliminate the 
transplant delay seen for patients using a public payer. This study has made it 
apparent that there is a significant delay for the patients having public assistance, 
and by making it known, more time and energy can be spent towards speeding 
up the process of this timeliness of care. One of the areas that needs fixed, and 
  
 
 
 
 
 38 
was found as a significant factor in our study, is rural healthcare. If patients in 
rural Nebraska are seeing more of delay, then a larger emphasis needs to be 
placed on rural medicine than what it is today, to allow patients in rural areas the 
same quality of care as those in urban areas. This study has allowed us to see 
areas of weakness within both the insurance company and hospital systems. The 
hope is that by having this knowledge, it will encourage the medical community 
and payer companies to begin examining ways to overcome these issues.     
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